Adzynma Wins FDA Approval as First Treatment for Ultra-Rare Blood Clotting Disorder cTTP
XTalks
NOVEMBER 10, 2023
cTTP is a very rare, inherited and life-threatening blood clotting disorder caused by a disease-causing mutation in the ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin motifs 13) gene, which encodes the ADAMTS13 enzyme that regulates blood clotting by cleaving the von Willebrand factor (VWF) protease.
Let's personalize your content